Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1993-7-8
|
| pubmed:abstractText |
A sustained release system for interleukin-2 (IL-2), and IL-2 mini-pellet (IL-2 mp), was developed by fusing IL-2 into a needle shaped collagen. Serum concentration of IL-2 after a single subcutaneous injection of the IL-2 mp into C57BL/6 mice remained elevated longer than after an injection of aqueous IL-2. IL-2 in the serum became undetectable by 6h after a subcutaneous injection of 1 x 10(6) unit of IL-2 in phosphate-buffered saline (PBS). In contrast, after a single subcutaneous injection of IL-2 mp containing the same amount of IL-2, the concentration of IL-2 increased to its maximum at 6h after injection, then began to decrease gradually. IL-2 was detected even on the third day after a single subcutaneous injection of one IL-2 mp. Augmentation of NK activity and generation of IL-2 activated killer cells were observed in the spleen from day 1--day 3 after a single subcutaneous injection of IL-2 mp into C57BL/6 mice. This activation was not observed following a single subcutaneous injection of the same amount of IL-2 in PBS. Adoptive immunotherapy by a single subcutaneous injection of IL-2 mp followed by intravenous injections of in vitro cultured IL-2 activated killer cells showed better results in decreasing the number of metastases of Lewis lung carcinoma in C57BL/6 mice than immunotherapy using IL-2 solution.(ABSTRACT TRUNCATED AT 250 WORDS)
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0386-300X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
47
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
79-84
|
| pubmed:dateRevised |
2003-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:8506753-Animals,
pubmed-meshheading:8506753-Delayed-Action Preparations,
pubmed-meshheading:8506753-Disease Models, Animal,
pubmed-meshheading:8506753-Drug Implants,
pubmed-meshheading:8506753-Female,
pubmed-meshheading:8506753-Immunotherapy, Adoptive,
pubmed-meshheading:8506753-Interleukin-2,
pubmed-meshheading:8506753-Killer Cells, Lymphokine-Activated,
pubmed-meshheading:8506753-Killer Cells, Natural,
pubmed-meshheading:8506753-Lung Neoplasms,
pubmed-meshheading:8506753-Mice,
pubmed-meshheading:8506753-Mice, Inbred C57BL,
pubmed-meshheading:8506753-Spleen
|
| pubmed:year |
1993
|
| pubmed:articleTitle |
Immunotherapy by a slow delivery system of interleukin-2 in mice models.
|
| pubmed:affiliation |
Okayama Central Hospital, Japan.
|
| pubmed:publicationType |
Journal Article
|